Effects of Combination Denosumab and High‐Dose Teriparatide Administration on Bone Microarchitecture and Estimated Strength: The DATA‐HD HR‐pQCT Study

In postmenopausal women at high risk of fracture, we previously reported that combined denosumab and high‐dose (HD; 40 μg) teriparatide increased spine and hip bone mineral density (BMD) more than combination with standard‐dose teriparatide (SD; 20 μg). To assess the effects of these combinations on bone microarchitecture and estimated bone strength, we performed high‐resolution peripheral quantitative computed tomography (HR‐pQCT) at the distal...